I like the idea of taking the money when it's available, within reason of course, especially if it can advance strategic goals.
I watched an interview with the CEO of Hepion Pharmaceuticals recently, they have a drug in early clinical trials. He talked about what he learned in his first stint as the CEO of another small clinical-stage pharma and he said his biggest mistake was not taking the money when it was there. You add to the coffers when you have the opportunity and move forward.
Looking at Perceptive, they are not a small-time operation. They have a broad portfolio that includes investments in 30+ public biotechs and many more private companies.
Ann: USD 20M Placement - Perceptive Advisors, page-11
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.86 |
Change
-0.140(1.40%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $69.04K | 7.028K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 60 | $10.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.61 | 1 | 1 |
View Market Depth
| Last trade - 15.59pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |